• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Significant response to targeted treatment with alectinib for intramedullary pediatric spinal high-grade glioma with ALK fusion.

作者信息

Ringel Amit, Elhasid Ronit, Constantini Shlomi, Roth Jonathan, Dvir Rina

机构信息

Department of Pediatric Hemato-Oncology, Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel.

Deparment of Pediatric Neurosurgery, Tel Aviv Medical Center, Tel Aviv, Israel.

出版信息

Pediatr Blood Cancer. 2023 Jul;70(7):e30312. doi: 10.1002/pbc.30312. Epub 2023 Mar 25.

DOI:10.1002/pbc.30312
PMID:36965191
Abstract
摘要

相似文献

1
Significant response to targeted treatment with alectinib for intramedullary pediatric spinal high-grade glioma with ALK fusion.对于伴有ALK融合的小儿脊髓高级别胶质瘤，使用阿来替尼进行靶向治疗有显著反应。
Pediatr Blood Cancer. 2023 Jul;70(7):e30312. doi: 10.1002/pbc.30312. Epub 2023 Mar 25.
2
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.克唑替尼耐药的间变性淋巴瘤激酶（ALK）重排非小细胞肺癌（NSCLC）患者中艾乐替尼针对全身疾病和脑转移的安全性和活性：一项 1/2 期研究剂量探索部分的结果。
Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.
3
Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.新型 SSFA2-ALK 融合的肺腺癌患者对阿来替尼的显著反应。
Invest New Drugs. 2022 Oct;40(5):1160-1163. doi: 10.1007/s10637-022-01260-4. Epub 2022 May 24.
4
Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.日本间变性淋巴瘤激酶阳性非小细胞肺癌患者的治疗序贯：一项真实世界观察性研究。
Adv Ther. 2020 Jul;37(7):3311-3323. doi: 10.1007/s12325-020-01392-0. Epub 2020 May 29.
5
Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.阿来替尼对 RET 重排的非小细胞肺癌显示出强大的抗肿瘤活性。
Mol Cancer Ther. 2014 Dec;13(12):2910-8. doi: 10.1158/1535-7163.MCT-14-0274. Epub 2014 Oct 27.
6
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.真实世界数据评估一线阿来替尼治疗晚期 ALK 阳性非小细胞肺癌患者的疗效和安全性：土耳其肿瘤学会研究。
Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083. Epub 2022 Jun 23.
7
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.阿来替尼可挽救先前接受过克唑替尼和色瑞替尼治疗的ALK阳性肺癌患者的中枢神经系统复发。
J Thorac Oncol. 2015 Feb;10(2):232-6. doi: 10.1097/JTO.0000000000000455.
8
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.选择性ALK抑制剂阿来替尼在颅内转移模型中的抗肿瘤活性。
Cancer Chemother Pharmacol. 2014 Nov;74(5):1023-8. doi: 10.1007/s00280-014-2578-6. Epub 2014 Sep 10.
9
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.阿来替尼对比克唑替尼用于治疗 ALK 阳性非小细胞肺癌患者（J-ALEX）：一项开放标签、随机、III 期临床试验。
Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.
10
Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.一线阿来替尼治疗罕见 ALK 基因融合的非小细胞肺癌患者的混合反应：病例系列和文献复习。
J Cell Mol Med. 2021 Oct;25(19):9476-9481. doi: 10.1111/jcmm.16897. Epub 2021 Sep 19.

引用本文的文献

1
Pediatric-type high-grade glioma of the spinal cord in the molecular era: institutional case series and updated systematic review of the literature.分子时代的小儿型脊髓高级别胶质瘤：机构病例系列及文献的最新系统综述
Childs Nerv Syst. 2025 Jun 2;41(1):200. doi: 10.1007/s00381-025-06856-8.
2
Frequent detection of genetic aberrations reveals novel pathogenesis and treatment modalities in systemic juvenile xanthogranuloma.频繁检测到的基因畸变揭示了系统性幼年性黄色肉芽肿的新发病机制和治疗方式。
Pediatr Investig. 2023 Aug 28;7(3):212-215. doi: 10.1002/ped4.12398. eCollection 2023 Sep.